Generic Name:
daunorubicin and cytarabine
Project Status:
Complete
Therapeutic Area:
Acute myeloid leukemia
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Brand Name:
Vyxeos
Project Line:
Reimbursement Review
Project Number:
PC0237-000
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adults with newly diagnosed therapy-related
acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes
(AML-MRC).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.